Press Releases

Press Releases

These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools.

Jul 29, 2020
Video Meeting on Thursday August 6, 2020 from 8:30 - 10:30 am LEXINGTON, Mass., July 29, 2020 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to
Jun 17, 2020
LEXINGTON, Mass., June 17, 2020 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies and cancer vaccines, announced today that Dr. Jennifer Buell, PhD, President and Chief Operating Officer of Agenus,
Jun 16, 2020
LEXINGTON, Mass., June 16, 2020 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers and infectious diseases, announces that it will host its 2020 Annual Shareholders Meeting virtually due to
Jun 02, 2020
- AgenTus allogeneic iNKTs have potential to clear SARS-CoV-2 virus & mitigate harmful inflammation - COVID-19 and cancer clinical trials to commence - Dr. Koen van Besien at Weill Cornell/New York Presbyterian Hospital to lead COVID-19 trials   LEXINGTON, Mass., June 2, 2020 / PRNewswire /
May 29, 2020
-- No complement mediated toxicities and up to 70% clinical benefit¹ across multiple solid tumors -- Combination of AGEN1181 with Agenus's balstilimab (PD-1) advancing in the clinic -- B. Riley to host conference call with Drs. Steven O'Day and Charles Drake on Next-Generation CTLA-4 agents - June